Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection
Whitepapers- Blood-based liquid biopsies are making inroads in cancer management and are increasingly used in conjunction with tissue biopsies. Plasma cfDNA, ctDNA and exoRNA can be used to molecularly profile cancer patients and guide downstream treatment decisions.
- Overall, data from four peer-reviewed articles indicate that plasma exoRNA/DNA combined with plasma cfDNA can be tested in a single qPCR test or through next generation sequencing panels — and this can increase the potential to detect patients with cancer, particularly those with early-stage disease. The ExoDx EGFR assay offers high sensitivity and specificity for EGFR mutations; and a low risk of false positives compared to cfDNA testing alone.
- The analysis of plasma exoRNA in combination with plasma cfDNA has potentially important implications in the molecular diagnosis of various conditions beyond cancer, including immunoinflammatory, musculoskeletal and neurodegenerative diseases
